ROS1 Translocations and NSCLC

Slides:



Advertisements
Similar presentations
Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.
Advertisements

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F R1. 임빈 / prof. 김시영
Phase I/II Study of Lorlatinib in Advanced ALK+ or ROS1+ NSCLC
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
Unità Clinica di Diagnostica Istopatologica e Molecolare
Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC
Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.
Advanced NSCLC Without Actionable Mutations
Fundamental Concepts in the Diagnosis of Advanced NSCLC
New Patient Journeys in Non-small cell lung cancer
Progression After Cancer Immunotherapy in Advanced NSCLC
The Genomics of Cancer and Molecular Testing:
New Standards of Care in ALK-Translocated Advanced NSCLC
Hemophilia Updates: Incorporating New Concepts Into Practice
Updates in Lung Cancer: Insights From Vienna
Optimizing Outcomes in the Management of GIST
Induction Chemotherapy for Patients With High-Risk or Secondary AML
Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.
Program Goals Introduction Case 1: A 44-Year-Old Woman.
Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors
Tailoring Hemophilia Prophylaxis Therapy
Recent Advances in Targeting ROS1 in Lung Cancer
T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference
The Evolving Role of Immunotherapy in NSCLC
More Than Meets the Eye.
Gene Therapy: Past, Present, and Future
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Immunotherapy for cSCC
Perspectives on the Impact of Inflammation in OA
Moving Care Forward in Advanced NSCLC
When Is Biologic Therapy Appropriate for HS?
Immune Checkpoint Inhibitors in Lung Cancer
The Road to Quality Improvement in HER2-Positive Breast Cancer
Locally Advanced Lung Cancer
Putting Evidence Into Practice: Highlights From Toronto
Battling the Flu: Latest Advances in the Influenza Treatment Arsenal
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Emerging Paradigms in ALK-Positive NSCLC
Understanding the Updated Guidelines for ALK Testing in NSCLC
Progress of the NSCLC Revolution
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.
Are We Making Progress in the Management of Huntington Disease?
Emerging Targets for the Diagnosis of Cancer
Optimizing Joint Health in Hemophilia
Practical Guidance on the Management of Pan-Negative NSCLC
Add-On Therapy to Insulin in T1DM Management
Proteasome Inhibitors and Patients
Practical Strategies to Guideline-Recommended Biomarker Testing in NSCLC.
Recent Advances in Targeting ROS1 in Lung Cancer
Novel Concepts in the Management of RCC
From Adjuvant to Metastatic in Melanoma
The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.
Educational Objectives
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition
AMD Therapy: Where Are We Now and Where Are We Going?
Checkpoint Inhibitors in First-Line Advanced NSCLC
Third-Generation EGFR TKIs
The Nurse View: Spotlight on EGFR-Mutated NSCLC
Real-World Evidence.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Finding the Right Sequence in Patients With EGFR-Mutated NSCLC
Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.
Identifying TRK Fusions in Head and Neck Cancer
ALK resistance mutations predict for sensitivity to lorlatinib in patient-derived cell line models of acquired resistance to ceritinib. ALK resistance.
Opening remarks Welcome to CUP 2019: Cancer of Unknown Primary in the Era of Precision Medicine Focus: Contemporary Clinical Management and International.
The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Updates in Best Practices in Non-Small Cell Lung Cancer
Presentation transcript:

ROS1 Translocations and NSCLC

Introduction

Introduction

Unique Features of ROS1-Rearranged NSCLC

Pathophysiology of ROS1

Identifying Appropriate Patients for ROS1 Testing in NSCLC

Identifying Appropriate Patients for ROS1 Testing in NSCLC

Methods for Detecting ROS1 Rearrangements

Crizotinib in ROS1-Rearranged NSCLC Overview

Crizotinib The PROFILE 1001 Trial

Crizotinib OxOnc, EUROS1, and the Metro Case Series

Crizotinib and Brain Metastases

Crizotinib Grade 3 TRAEs in ≥ 10% of Patients in the PROFILE 1001 Trial

Ceritinib in ROS1-Rearranged NSCLC Overview

Ceritinib Phase 2, Open-Label Trial

Entrectinib in ROS1-Rearranged NSCLC Overview and Integrated Dataset

Resistance to Crizotinib in ROS1-Rearranged NSCLC

Lorlatinib in ROS1-Rearranged NSCLC Overview

Lorlatinib Phase 2 ALK Registration Trial

Lorlatinib Phase 2 ALK Registration Trial (cont)

Repotrectinib in ROS1-Rearranged NSCLC Overview

Repotrectinib TRIDENT-1 Trial

Cabozantinib and Foretinib in ROS1-Positive NSCLC Overview

Considerations for Choosing Second-Line Therapy in ROS1-Rearranged NSCLC

Closing Remarks

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.